What’s Your Ki67?
September 2025
Bethany T. Samuelson Bannow, MD, MCR
Dr. Samuelson Bannow discusses the importance of having a growth mindset, using Ki67 as a metaphor.
Skip Nav Destination
Editor's Corner
Study Identifies CD38 Mutations That Confer Resistance to CD38-Targeting Antibodies in Patients with MM
September 2025
By analyzing whole-genome and whole-exome sequencing data from patients with multiple myeloma (MM) who were never treated with anti-CD38 monoclonal antibodies and those who relapsed following anti-CD38 antibody therapy, researchers have identified two types of genomic events involving CD38 and driving resistance mutations among patients who have been treated with anti-CD38 antibodies.
Bridging the Gap: How Hematology Can Better Support Patient Wellness
September 2025
Krisstina Gowin, DO, and Urvi A. Shah, MD, MS, discuss the importance of patient-centered wellness interventions in the field of hematology.
Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL
September 2025
Measurable residual disease (MRD)-guided therapy with the BTK inhibitor ibrutinib plus venetoclax in patients with treatment-naïve chronic lymphocytic leukemia (CLL) showed greater rates of undetectable MRD, extended progression-free survival (PFS), and increased overall survival, especially among patients with unmutated IGHV, compared to ibrutinib alone or chemoimmunotherapy.
